Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Water and Sudafed in Autonomic Failure
NCT02149901 · Vanderbilt University · EARLY_PHASE1 · terminated · last registry update 2021-05-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “funding terminated” | – | Registry record, Vanderbilt University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC6A2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-04-29Also stopped (terminated): Mansoura University, Orphenadrine + Baclofen (NCT04509336)
- 2022-04-22Results posted on the registry: University of Minnesota, Levomilnacipran + Placebo (NCT02265367)
- 2022-03-25Results posted on the registry: Allergan, Levomilnacipran ER + Fluoxetine (NCT03569475)
- 2022-03-18Phase 3 first posted: Cingulate Therapeutics, CTx-1301-Dexmethylphenidate 12.5 mg (titration only) + CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose) (NCT05286762)
- 2021-10-27Results posted on the registry: Supernus Pharmaceuticals, Inc., Placebo + 100mg SPN-812 (NCT02633527)
- 2021-09-09Also stopped (terminated): Wake Forest University Health Sciences, methylphenidate hydrochloride (NCT00031798)
- 2021-07-19Results posted on the registry: Zevra Therapeutics, KP415 oral capsule (NCT03460652)
- 2021-07-08Results posted on the registry: Supernus Pharmaceuticals, Inc., Placebo + 200mg SPN-812 (NCT03247543)
- 2021-07-02Results posted on the registry: Supernus Pharmaceuticals, Inc., Placebo + 400mg SPN-812 (NCT03247556)
- 2021-06-30Results posted on the registry: Zevra Therapeutics, KP415 oral capsule + Placebo oral capsule (NCT03292952)
- 2021-06-18Results posted on the registry: Supernus Pharmaceuticals, Inc., Placebo + 200mg SPN-812 (NCT03247517)
- 2021-06-08Also stopped (withdrawn): Sue O'Dorisio, 177Lu-DOTA-tyr3-OCTREOTATE (NCT03923257)
- 2021-06-02Results posted on the registry: Supernus Pharmaceuticals, Inc., Placebo + 100mg SPN-812 (NCT03247530)
- 2021-05-14Also stopped (terminated): Miguel Pampaloni, 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added) + 124I-MIBG (carrier added) (NCT01583842)
- 2021-04-23Results posted on the registry: St. Louis University, nortriptyline + Topiramate (NCT02169830)
- 2021-04-23Also stopped (terminated): St. Louis University, nortriptyline + Topiramate (NCT02169830)
- 2021-04-08Results posted on the registry: Cingulate Therapeutics, Dexmethylphenidate 5 Mg Oral Capsule, Extended Release + Dexmethylphenidate 6.25 mg Tablet (NCT04138498)
- 2021-03-05Also stopped (terminated): Temple University, Desipramine + Amitriptyline (NCT00220844)
- 2020-10-14Results posted on the registry: Federal University of Rio Grande do Sul, Lithium Carbonate + Sertraline (NCT02918097)
- 2020-10-14Results posted on the registry: Federal University of Rio Grande do Sul, sertraline + Nortriptyline (NCT02901249)
- 2020-09-07Results posted on the registry: Forest Laboratories, Placebo + Levomilnacipran (NCT02431806)
- 2020-09-03Results posted on the registry: Columbia University, Milnacipran + Placebo (NCT01288937)
- 2020-09-03Also stopped (terminated): Columbia University, Milnacipran + Placebo (NCT01288937)
- 2020-06-01Results posted on the registry: New York State Psychiatric Institute, Milnacipran and D-cycloserine (NCT02687165)
- 2020-06-01Also stopped (terminated): New York State Psychiatric Institute, Milnacipran and D-cycloserine (NCT02687165)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision